Evaluatie van actuele toepassing van BMX-010 bij personen met rosacea
Een verkennend onderzoek om de klinische effectiviteit van een plaatselijke toepassing van BMX-010 bij proefpersonen met rosacea te evalueren
This is an exploratory Phase 2 trial of BMX-010 in patients with Rosacea which will be conducted in two parts. Up to 210 subjects with Rosacea will be enrolled.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug. Up to 60 subjects will be enrolled in this part.
Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo. Up to 150 subjects will be enrolled in this part.
In both parts, adult subjects with Rosacea will be enrolled.
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Colorado
-
Englewood, Colorado, Verenigde Staten, 80113
- Colorado Skin Care
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female, at least 18 years of age;
- A clinical diagnosis of mild to severe facial rosacea;
- Screening and Baseline IGA score > 2 (greater than or equal to 2);
- A minimum Clinician Erythema Assessment (CEA) score of 2 at Screening and at Baseline Visits (prior to the investigational product application);
- Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
- Candidate for topical treatment of Rosacea;
- If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup;
- Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
- Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
- Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Any dermatological conditions on the face that could interfere with clinical evaluations;
- Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
- Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
- Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
- Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
- Use of medicated make-up (including anti-aging make-up) throughout the study;
- Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact rosacea, 4) immunosuppressive agents, or immunomodulators;
- Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics;
- Use of medicated cleansers on the face (throughout the study);
- Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
- Systemic or skin infection requiring antimicrobial therapy;
- Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
- Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
- Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
- Active drug or alcohol dependence;
- Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
- Previous clinical trial participation for the indication being treated in this protocol.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: BMX-010 0.03%
Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face. |
Safety and efficacy of BMX-010 in topical treatment of rosacea. |
|
Experimenteel: BMX-010 0.1%
Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face. |
Safety and efficacy of BMX-010 in topical treatment of rosacea. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Treatment Success Rate
Tijdsspanne: 43 days
|
The percentage of subjects will be reported that experience a clinically meaningful treatment success, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade from the baseline assessment prior to treatment to the final assessment two weeks after dosing ends (Day 43). |
43 days
|
|
Clinical Erythema Assessment (CEA): Clinically Meaningful Erythema Reduction Rate
Tijdsspanne: 43 days
|
Assessed by number of participants with at least a 2-point reduction in Clinical Erythema Assessment (CEA) grade from the baseline score prior to treatment to a final assessment two weeks after dosing ends (Day 43). |
43 days
|
|
Investigator Global Assessment (IGA) Grade: Rosacea Severity Change Over Treatment Period
Tijdsspanne: 28 days
|
The Investigator Global Assessment (IGA) grade, which will be assessed weekly, is a clinical assessment of disease severity. Scores range from 0 (clear) - 4 (severe). The change in IGA score from Baseline to 28 days of treatment will be reported. |
28 days
|
|
Clinical Erythema Assessment (CEA): Erythema Severity Change Over Treatment Period
Tijdsspanne: 28 days
|
The Clinical Erythema Assessment (CEA) grade will be assessed weekly. Grades range from 0 = clear/no erythema to 4 = severe/fiery red erythema. The change in CEA score from Baseline to 28 days of treatment will be reported. |
28 days
|
|
Investigator Global Assessment (IGA) Grade: Clinically Meaningful Rosacea Reduction During Treatment
Tijdsspanne: 28 days
|
The percentage of subjects will be reported that experience a clinically meaningful rosacea reduction, which is defined as a 2-point reduction in Investigator Global Assessment (IGA) grade over the treatment period of 28 days. |
28 days
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Photography Documenting Rosacea Symptoms in Patients Treated With BMX-010
Tijdsspanne: 43 days
|
If consented by the patient, photos will be taken at each study visit. The number of patients photographed will be reported. |
43 days
|
|
Change in Number of Inflammatory Papules/Pustules From Baseline to 43 Day Follow-up.
Tijdsspanne: 43 days
|
Inflammatory lesions will be counted at each study visit. The mean percent change in inflammatory papules/pustules counts from baseline to the final (day 43) follow-up will be reported. |
43 days
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- BMX-DERM-202
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .